Your support fuels our research to #EndALS! Donate Now
Quick Info
Currently Recruiting
Trial Type
Treatment Type
Drug Trials
Not Available
Start Date
Transposon Therapeutics, Inc.
Contact Information
    Contact information unknown.
United States, Massachusetts
Massachusetts General Hospital, Boston, MA, 02114, United States
Contact: James Berry, MD, MPH
Enrollment Criteria
Breathing Ability
Percent lung function (FVC) or (SVC)
>60% (SVC)
Months Since Onset
Number of months since first symptoms of ALS.
<3 Years
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
Diaphragm Pacer (DPS)
Can PALS use a DPS in the trial?
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Open Label
Update Notes
Study recruiting
Outcome measures updates

Other Information

This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).
Inclusion Criteria:
- Have documentation of a clinical genetic test demonstrating the presence of a confirmed repeat expansion in the C9orf72 gene from a CLIA certified laboratory - Score ≥ 18 on the Mini-Mental State Exam (MMSE) at Screening - Have a reliable caregiver to accompany the patient to all study visits.
- For patients with ALS (with or without FTD):
- Diagnosis of ALS (probable, possible, laboratory-supported probable or definite) according to the World Federation of Neurology revised E1 Escorial criteria - Onset of weakness within 3 years prior to Screening - Slow vital capacity (SVC) ≥ 60% of predicted normal adjusted for sex, age, and height (from the sitting position) - ALS Functional Rating Scale-Revised (ALSFRS-R) ≥ 30 at Screening - For patients with FTD:
- A gradual, progressive decline in behavior, language, or motor function consistent with C9ORF72 hexanucleotide expansion-related syndrome such as behavioral variant FTD, primary progressive vaphasia, or amnestic syndrome - CDR Dementia Staging Instrument plus National Alzheimer's Coordinating Center Behavior and Language Domains (CDR plus NACC FTLD) global score of 0.5-2.0 at Screening Exclusion Criteria:
- Presence of other significant neurological or psychiatric disorders - History of significant brain abnormality, including, but not limited to, prior hemorrhage or infarct, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma); symptoms or signs of elevated intracranial pressure, e.g., symptoms or history of head injury or abnormal funduscopic exam. If there is history or evidence on neurologic exam suggesting possible subdural hematoma (SDH), patients should be fully evaluated, including magnetic resonance imaging (MRI) if indicated, to exclude significant, new SDH
This is a Phase 2a multi-center, randomized, double-blind, placebo-controlled parallel-group, 2-arm study with a long-term, open-label treatment phase in patients with C9ORF72 ALS and/or FTD. This study includes a 6-week Screening Period, a 24-week Double-blind Treatment Period, a 24-week Open-label Treatment Period, and a Follow-up Visit 4 weeks post-treatment.
  • Transposon Therapeutics, Inc.
Trial Protocol as Published on
NCT04993755 (First Published: 7/19/2021)